Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,931 | -6,151 | -3,602 | -11,480 | -8,749 |
| Depreciation Amortization | 46 | 31 | 16 | 71 | 56 |
| Accounts payable and accrued liabilities | -606 | -138 | 123 | 496 | 260 |
| Other Working Capital | 117 | 373 | 736 | -1,256 | -1,194 |
| Other Operating Activity | 995 | 406 | 19 | 40 | 203 |
| Operating Cash Flow | $-8,379 | $-5,479 | $-2,708 | $-12,129 | $-9,424 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5 | -5 | N/A | -121 | -121 |
| Investing Cash Flow | $-5 | $-5 | $N/A | $-121 | $-121 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,048 | 5,048 | N/A | N/A | N/A |
| Common Stock Repurchased | -11 | -11 | -11 | N/A | N/A |
| Other Financing Activity | -27 | -27 | -27 | -26 | -28 |
| Financing Cash Flow | $5,010 | $5,010 | $-38 | $-26 | $-28 |
| Beginning Cash Position | 11,831 | 11,831 | 11,831 | 24,107 | 24,107 |
| End Cash Position | 8,457 | 11,357 | 9,085 | 11,831 | 14,534 |
| Net Cash Flow | $-3,374 | $-474 | $-2,746 | $-12,276 | $-9,573 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,379 | -5,479 | -2,708 | -12,129 | -9,424 |
| Capital Expenditure | -5 | -5 | N/A | -121 | -121 |
| Free Cash Flow | -8,384 | -5,484 | -2,708 | -12,250 | -9,545 |